EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Review Article: Drug Approval for Gastroparesis—Suggestions for Improving the Process for Positive Results

Michael Camilleri iD, Henry P Parkman

Alimentary Pharmacology & Therapeutics · 2026

DOI: 10.1111/apt.70544 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2026. Verfasst von Michael Camilleri und 1 weiteren Autor:innen. Beteiligte Einrichtung: Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Gastroparesis, Drug Approval, Metoclopramide, Gastrointestinal Agents. Die Arbeit nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In the United States, metoclopramide is the only medication approved for gastroparesis. There is a need to reappraise the main considerations involved in the approval of pharmacological treatments of gastroparesis. Objectives and Methods We conducted a literature review to address issues that might impact the approval of medications for gastroparesis. We appraised the epidemiology, clinical presentations, variations in diagnostic tests, and their thresholds for identification of gastroparesis. Based on the review, we proposed trial designs for proof of efficacy and safety of novel medications for gastroparesis.

Results

Based on epidemiological studies, the age‐adjusted prevalence in US population is 152,005 for all categories (definite, probable and possible) of gastroparesis. The major symptoms of gastroparesis are nausea, vomiting, early satiety and postprandial fullness and may lead to hospitalisation or emergency department visits. It is essential to appraise gastric emptying with a solid meal over at least 3 h using scintigraphy or a stable isotope breath test. Diagnostic thresholds have been established for these diagnostic tests and at present, reproducibility, normative data, and coefficient of variation are well established for the 320‐kcal real egg solid meal. Based on published guidelines on clinical efficacy of medications used in gastroparesis, we propose targeting the gastroparesis symptom subscales, such as nausea and vomiting, with pharmacological agents specifically directed at their causative mechanisms rather than targeting the underlying dysmotility.

Conclusion

The evidence documented here justifies consideration of gastroparesis as an orphan disease, as well as an innovative approach to supplement the regulatory bodies' recommendations and guidance to industry. We propose treatment trials of 4‐weeks duration and considering the use of specific symptoms of gastroparesis as clinical endpoints based on a pharmaceutical agent's mechanism of action, rather than using a total gastroparesis symptom score. Such an approach would include evidence of safety and efficacy of new medications targeting gastroparesis subscales, and approval for marketing would be based on the symptoms specifically ameliorated in robust trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GastroparesisDrug ApprovalMetoclopramideGastrointestinal AgentsAntiemeticsHumansGastric EmptyingUnited States

Substanzen

MetoclopramideGastrointestinal AgentsAntiemetics

Autor:innen und Institutionen

  • Mayo Clinic, Rochester, Minnesota, USA.
  • Temple University, Philadelphia, Pennsylvania, USA.

ORCID-Profile: Michael Camilleri

Zitieren

APA

Camilleri, M., & Parkman, H. P. (2026). Review Article: Drug Approval for Gastroparesis—Suggestions for Improving the Process for Positive Results. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70544

Vancouver

Camilleri M, Parkman HP. Review Article: Drug Approval for Gastroparesis—Suggestions for Improving the Process for Positive Results. Alimentary Pharmacology & Therapeutics. 2026. doi:10.1111/apt.70544

BibTeX
@article{Camilleri2026,
  author = {Camilleri, Michael and Parkman, Henry P},
  title = {Review Article: Drug Approval for Gastroparesis—Suggestions for Improving the Process for Positive Results},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2026},
  doi = {10.1111/apt.70544}
}
Kostenlos starten →